Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit
Launch innovative vitamin sublingual sprays
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Subscribe To Our Newsletter & Stay Updated
